Reteplase with or without abciximab for peripheral arterial occlusions: Efficacy and adverse events

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 6, 2004, Pages 557-564

  Hull, Jeffrey Eaton ^a   Hull, Mary Kathryn ^a   Urso, James A ^a  

^a CJW Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; RETEPLASE; TIROFIBAN; UROKINASE;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BYPASS SURGERY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG USE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEMATOMA; HEMOPTYSIS; HUMAN; HYPOTENSION; INCIDENCE; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2942565675     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000127891.54811.02     Document Type: Article

References (35)

1. Hartnell GG, Gates J. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States. J Vasc Interv Radiol 2000; 11:841-847.
2. Gates J, Hartnell GG. When urokinase was gone: commentary on another year of thrombolysis without urokinase. J Vasc Interv Radiol 2004; 15:1-5.
3. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 2000; 11:149-161.
4. Tepe G, Schott U, Erley CM, Albes J, Claussen CD, Duda SH. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. AJR Am J Roentgenol 1999; 172:1343-1346.
5. Duda SH, Tepe G, Luz O, et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone-a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis. Radiology 2001; 221:689-696.
6. Drescher P, Crain MR, Rilling WS. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study. J Vasc Interv Radiol 2002; 13:37-43.
7. Rutherford R, Baker J, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-538.
8. Patel N, Sacks D, Patel RI, et al. SCVIR reporting standards for the treatment of acute limb ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol 2001; 12:559-570.
9. Weitz JI. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol 1995; 6(suppl):19S-23S.
10. Tepe G, Luz O, Hahn U, et al. Pulsed spray lysis with reteplase in peripheral arterial occlusions-technique and initial results. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2000; 172:780-784. [German]
11. Davidian MM, Powell A, Benenati JF, Katzen BT, Becker GJ, Zemel G. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000; 11: 289-294.
12. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000; 11:849-854.
13. Diffin DC, Kandarpa K. Assessment of peripheral intraarterial thrombolysis versus surgical revascularization in acute lower-limb ischemia: a review of limb-salvage and mortality statistics. J Vasc Interv Radiol 1996; 7:57-63.
14. Goh RH, Sniderman KW, Kalman PG. Long-term follow-up of management of failing in situ saphenous vein bypass grafts using endovascular intervention techniques. J Vasc Interv Radiol 2000; 11:705-712.
15. Greenberg RK, Ouriel K. A multimodal approach to the management of bypass graft failure. Vasc Med 1998; 3:215-220.
16. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999; 34:1395-1402.
17. Benenati J, Shlansky-Goldberg R, Meglin A, Seidl E. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology. J Vasc Interv Radiol 2001; 12:795-805.
18. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:1466-1473.
19. STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg 1994; 220:251-266.
20. Meyerovitz MF, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990; 175:75-78.
21. Bero CJ, Cardella JF, Reddy K, et al. Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. J Vasc Interv Radiol 1995; 6:571-577.
22. McNamara TO, Dong P, Chen J, et al. Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and venous thromboembolic occlusions. Tech Vasc Interv Radiol 2001; 4:92-98.
23. Stewart RJ, Fredenburgh JC, Leslie BA, Keyt BA, Rischke JA, Weitz JI. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000; 275:10112-10120.
24. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111:1010-1022.
25. Marder VJ. Bleeding complications of thrombolytic treatment. Am J Hosp Pharm 1990; 47(suppl):S15-S19.
26. Castaneda F, Swischuk JL, Li R, Young K, Smouse B, Brady T. Declining-dose study of reteplase treatment for lower extremity arterial occlusions. J Vasc Interv Radiol 2002; 13:1093-1098.
27. Bookstein JJ, Bookstein FL. Pulse-spray thrombolysis with reteplase: optimization and comparison with tPA in a rabbit model. J Vasc Interv Radiol 2001; 12:1319-1324.
28. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101:2788-2794.
29. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-1914.
30. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000; 21:1944-1953.
31. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99:2720-2732.
32. Kwon OK, Lee KJ, Han MH, Oh CW, Han DH, Koh YC. Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases. AJNR Am J Neuroradiol 2002; 23:447-451.
33. Lee DH, Jo KD, Kim HG, et al. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol 2002; 13:769-774.
34. Dillon WC, Eckert GJ, Dillon JC, Ritchie ME. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. Cathet Cardiovasc Intervent 2000; 50:426-430.
35. Razavi MK, Lee DS, Hofmann LV. Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies. J Vasc Interv Radiol 2004; 15:13-23.